Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
about
Recent Developments of Liposomes as Nanocarriers for Theranostic Applications.Nanotechnology: Future of OncotherapyThe potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivoSite-specific functionalization of proteins and their applications to therapeutic antibodiesTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyThe development of immunoconjugates for targeted cancer therapyTargeted therapy using nanotechnology: focus on cancerSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesNanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.Nanooncology: the future of cancer diagnosis and therapy.Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors.Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Antibody-targeted biodegradable nanoparticles for cancer therapy.Cancer drug delivery in the nano era: An overview and perspectives (Review)Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy.Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.Antibody-targeted nanoparticles for cancer treatment.Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors.Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines.Improved Targeting of Cancers with Nanotherapeutics.Liposome-targeted delivery for highly potent drugs.Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection.Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.Trial watch: Chemotherapy with immunogenic cell death inducers.All-trans retinoic acid-encapsulated, CD20 antibody-conjugated poly(lactic--glycolic acid) nanoparticles effectively target and eliminate melanoma-initiating cells in vitrosiRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells
P2860
Q26744835-3597E541-47FD-49A9-8942-E2C2D4133DBAQ26801067-37C26FCF-6E5F-4263-BD0D-26E2D21DDDF2Q26827175-27C0BA02-2E94-4506-B60B-590C3050105EQ26830699-D56BEEA3-660D-4F54-8A6E-9C91EF4350FCQ26993238-B791F178-6BF7-402F-B447-166B3981C0DFQ27021990-A53D0637-52B7-4148-AF87-D5A05C8DF093Q27023361-733DA8A8-3772-492E-80BF-6803A6443B34Q30358389-343770C6-32AC-42A6-8967-BFDE21785EF0Q33681168-D534A896-4CF3-43A2-8C79-20B585E4F9ACQ33925422-DE6CE484-1CAB-4065-9DCD-9134154D239EQ34447986-9E318843-0EB8-47D9-8502-77DD28BE9909Q36962480-DAA72C80-D3B3-45C1-B8E7-D5DB0C2854E8Q37115994-7DC296A5-A8F5-46DC-A6E2-69D6C61169E1Q38084826-567C7CB8-33A0-4FB4-AD92-E2039832B8E5Q38117056-DB533536-535E-4E70-9936-AEF88BC8125CQ38151549-00F2AB54-4EC1-4013-A9E1-3B9BC1D1BABEQ38169752-5F01B707-666F-4742-AB46-98D6FE1DB343Q38271422-4E5DE142-995B-44CC-8780-63FE3464814FQ38328927-32C8959D-B163-41A9-8733-B41788D32B0CQ38577297-48C33C09-0B4B-40AB-8AA0-902FA18D7AECQ38665261-E56E6CB2-688E-4C58-9D7F-7BCFE2FDBB28Q38669454-21F643A0-B056-4117-A4F0-1B90AEFA1A22Q38676164-4E4A8539-063A-40F0-A13F-13C6B4331FFEQ38787937-175F07BA-F253-451C-905E-6C7C2A2C5270Q38850036-5EA5037E-7D97-4BFA-B715-F9DC758184E5Q38854876-0C572F03-37A3-40A0-B15E-31B6C04DE081Q38887307-D66BFBC8-58C7-4E53-A02D-387A914586B6Q38978632-918614AE-0CAE-48D0-8904-FAE413CC04D0Q38981743-44C1EF62-17B1-48CC-A08B-FC30B64CA446Q39034610-5B27377D-74FE-4675-9A78-AAD5CDB4337FQ39114835-48E97DDA-1787-4188-9B24-058CE3F8C1F3Q39171223-E3557C40-7C3A-429E-B894-634B12F034C2Q49218382-78C55CB2-13FA-47BD-BB3F-68D5EE162FE3Q53132713-D102D1D7-E96F-4334-A8C2-D04F0132675DQ55105383-847BE6DF-44CE-4ECC-AFF9-A1A1C881CBB4Q55285429-9EBBD860-9D11-4201-A4D0-430A59738BD2Q55658029-9DBF972A-92CE-4246-8700-9FB15E9AE93FQ57069994-4C5B1AE0-ED97-4272-B2DA-C0F60FDDE91FQ57816012-E20E00A4-B872-46FE-83E7-ABCC284DCDEB
P2860
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study.
@en
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study.
@nl
type
label
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study.
@en
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study.
@nl
prefLabel
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study.
@en
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study.
@nl
P2093
P50
P1433
P1476
Tolerability, safety, pharmaco ...... phase 1 dose-escalation study
@en
P2093
Christoph Hilker
Christoph Rochlitz
Gregor Stehle
Lukas Bubendorf
Reto Ritschard
Richard Herrmann
Stefanie Deuster
P304
P356
10.1016/S1470-2045(12)70476-X
P577
2012-11-13T00:00:00Z